Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
about
DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsEpigenetic treatment of solid tumours: a review of clinical trialsExploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation AssaysA phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancerGrowth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivoEpigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancerHistone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells.[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.Autophagic and apoptotic effects of HDAC inhibitors on cancer cellsInterpreting clinical assays for histone deacetylase inhibitors.Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.Drug monographs: belinostat and idelalisib.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Bortezomib and belinostat inhibit renal cancer growth synergistically by causing ubiquitinated protein accumulation and endoplasmic reticulum stress.Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancerHR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.The future of epigenetic therapy in solid tumours--lessons from the past.Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary report.Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid MalignanciesEpigenetics in cancer stem cells.Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical reviewBelinostat: clinical applications in solid tumors and lymphoma.Targeting the epigenome in ovarian cancer.Clinical trials and future potential of targeted therapy for ovarian cancer.Toxicological and metabolic considerations for histone deacetylase inhibitors.Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.Histone deacetylase inhibitors in hematological malignancies and solid tumors.Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.An overview of early investigational therapies for chemoresistant ovarian cancer.Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinomaPaclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
P2860
Q26749421-83989B86-265D-400F-95C4-241671894CB6Q26773803-81CAD9B7-0CF8-4505-B62E-27E11E5C7635Q28550025-F7BB1AD5-8CAF-4FBA-BA6D-A10289956251Q33399902-59BEBF55-91D7-4961-9095-BE7F96AC7A8EQ33659166-EE0E74A7-EED4-4E8A-AA49-D34B81BCF731Q33927370-BEECA574-E0A2-4779-B376-C90961E9C56EQ34305438-850D56F6-989B-4E59-9DC0-F6FC1F3BBAB1Q34416994-FC7F5908-9553-4222-8A11-1540F400CEC0Q34488424-706CDFFA-09C8-4985-A466-167B22128679Q34575453-0C870F77-E29D-4A8C-8BB5-E7223F7EACAEQ34638065-8EC8B767-5D88-4433-A7BF-C460DA540B1AQ34645445-29861317-054C-4468-8AC7-4342F09D3214Q34878868-273BD2B2-D4E8-4F7D-BD95-A9DB96D3AD9DQ35001459-05075337-99DD-4ABC-8BFD-16B0424F7855Q35003657-4084890C-260E-4100-B504-A691684208BEQ35016964-CD7E2755-0B23-492B-BF37-8FC51111F189Q35057942-7BB8ECB9-F115-46B8-A405-6BB35BE70339Q35214924-57E5500B-0659-44D0-89AF-567C6F92B345Q35556061-ADE60F60-E053-4E01-812E-289FB69E802EQ35726371-A2473E0A-F48D-47A5-B8EF-07FE4172B570Q35939690-6A0CB2C2-2A07-4E30-8FA1-EA917CE56271Q36321535-ADDBFB36-E867-449D-A635-E992DD0DEA97Q36537920-AC23AF6F-760E-49BC-9DF7-BA8831965036Q37002069-DBFD1FBF-460D-4F2E-956C-C1B911059573Q37061554-182A48D1-BAB8-4BA5-857F-1BDF9D23CA31Q37222794-30530BF5-2031-4079-BDD3-9A703A5A870EQ37226511-F8781361-6782-4E24-90BF-9229B98A2257Q37618640-E6A5FE81-E082-4E9E-8F9A-E6FF2195BB6AQ37702543-EED4F72C-95AF-448B-A31A-4910FBD04E3DQ37724905-D63FC48D-0FBE-4324-8FBC-CD14C55C7100Q37951994-C04A90AF-3F4F-40B7-97F2-7522AEA1F706Q37984122-D47C9EE9-4582-483A-95BE-22832598C0AAQ38038489-B23D2F5C-79C9-44D8-84F6-2E84E8FD57CCQ38071321-2EDD144E-180B-486B-BAFE-E9BB513AD2D4Q38081988-E4D3FF83-F403-48BD-9A60-0349D7D8E144Q38344675-9771FB08-75E7-4BC2-9273-6941090D07F8Q38544386-44C0FDB0-4E1E-4817-AFE7-41C470BD3D7BQ38553247-F1BA5D65-1CD0-42D1-8C56-4BE040BBD38AQ38843100-D92180F6-0A1C-4B5C-A312-0736490675CFQ39051716-D9D1424D-0C93-436A-A6E6-5C93C4955882
P2860
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Phase II trial of the histone ...... pillary (LMP) ovarian tumours.
@ast
Phase II trial of the histone ...... pillary (LMP) ovarian tumours.
@en
type
label
Phase II trial of the histone ...... pillary (LMP) ovarian tumours.
@ast
Phase II trial of the histone ...... pillary (LMP) ovarian tumours.
@en
prefLabel
Phase II trial of the histone ...... pillary (LMP) ovarian tumours.
@ast
Phase II trial of the histone ...... pillary (LMP) ovarian tumours.
@en
P2093
P2860
P1476
Phase II trial of the histone ...... apillary (LMP) ovarian tumours
@en
P2093
Amit M Oza
Helen J Mackay
James Zwiebel
Jaqueline Mason
Katrina MacAlpine
Pamela Grenci
P2860
P304
P356
10.1016/J.EJCA.2010.02.047
P577
2010-03-19T00:00:00Z